TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF

TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF

Disclosed is an isolated antibody or binding fragment thereof that specifically binds to PDGFR-alpha and inhibits the growth of cells that express PDGFR-alpha comprising: a heavy chain complementarity determining region (CDR) 1 comprising the amino acid sequence GFTFSDYYMN; a heavy chain CDR2 compri...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BLAKEY, DAVID, CHARLES, KANG, JASPAL, SINGH, FOLTZ, IAN, LAING, NAOMI, GAZIT-BORNSTEIN, GADI, CARTLIDGE, SUSAN, ANN, YANG, XIADONG, TAYLOR, LAURA
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Disclosed is an isolated antibody or binding fragment thereof that specifically binds to PDGFR-alpha and inhibits the growth of cells that express PDGFR-alpha comprising: a heavy chain complementarity determining region (CDR) 1 comprising the amino acid sequence GFTFSDYYMN; a heavy chain CDR2 comprising the amino acid sequence YISSSGSIIYYADSVKG; a heavy chain CDR3 comprising the amino acid sequence EGRIAARGMDV; a light chain CDRI comprising the amino acid sequence RPSQSFSRYIN; a light chain CDR2 comprising the amino acid sequence AASSLVG; and a light chain CDR3 comprising the amino acid sequence QQTYSNPPIT. Also disclosed is the use of the antibody in the preparation of a medicament for the treatment of a neoplastic disease and cancer